

Mark A. Pals, P.C. (*pro hac vice*)  
mpals@kirkland.com  
Marcus E. Sernel, P.C. (*pro hac vice*)  
msernel@kirkland.com  
KIRKLAND & ELLIS LLP  
300 North LaSalle  
Chicago, IL 60654  
(312)862-2000 (o); (312)862-2200 (f)

Daralyn J. Durie (SBN 169825)  
ddurie@durietangri.com  
Mark Lemley (SBN 155830)  
mlemley@durietangri.com  
DURIE TANGRI LLP  
217 Leidesdorff Street  
San Francisco, CA 94111  
(415)362-6666 (o); (415)236-6300 (f)

Attorneys for GENENTECH, INC.

David I. Gindler (SBN 117824)  
dgindler@irell.com  
Joseph M. Lipner (SBN 155735)  
jlipner@irell.com  
IRELL & MANELLA, LLP  
1800 Avenue of the Stars  
Los Angeles, CA 90067  
(310)277-1010 (o); (310)203-7199 (f)

Attorneys for CITY OF HOPE

**UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA  
WESTERN DIVISION**

CENTOCOR ORTHO BIOTECH,  
INC. ,

Plaintiff,

v.

GENENTECH, INC. and CITY OF  
HOPE,

Defendants.

GENENTECH, INC. AND CITY OF  
HOPE,

Counter-Plaintiffs

v.

CENTOCOR ORTHO BIOTECH,  
INC.

Counter-Defendant

AND

GLOBAL PHARMACEUTICAL  
SUPPLY GROUP, LCC, CENTOCOR  
BIOLOGICS, LLC, AND JOM  
PHARMACEUTICAL SERVICES,  
INC.

Third-party Defendants.

Case No. CV 08-03573 MRP (CTx)

The Honorable Mariana R. Pfaelzer

**[PROPOSED] ORDER  
AMENDING THE OCTOBER 20,  
2009 STIPULATED  
PROTECTIVE ORDER**

1 Having considered Genentech Inc.'s Motion to Amend the Stipulated  
2 Protective Order, Centocor Ortho Biotech Inc.'s opposition thereto, and the  
3 arguments of the parties for and against the Motion, and for the reasons explained  
4 at the July 19, 2010 hearing on the Motion,

5 IT IS HEREBY ORDERED THAT:

6 1. The Stipulated Protective Order entered by this Court in this matter on  
7 October 20, 2009 is hereby amended to incorporate Paragraph 26 as follows:

8 "26. Notwithstanding the foregoing, certain Confidential Material produced  
9 by Centocor consisting of (1) the Patent License Agreement between Celltech  
10 Therapeutics Limited ("Celltech") and Centocor dated March 31, 1998; (2) the  
11 Patent License Agreement between UCB Pharma S.A./UCB Celltech and  
12 Centocor dated October 1, 2008 and all collateral agreements between those  
13 parties dated on or around October 1, 2008; (3) correspondence between Centocor  
14 and Celltech concerning such agreements identified in the June 17, 2010 letter of  
15 Hannah Williams to Allen Norris; and (4) portions of the deposition testimony of  
16 Ken Dow (dated August 12, 2009) and Nicholas D'Aleandro (dated August 12,  
17 2009) concerning such agreements (collectively the "Potential Arbitration  
18 Material") may be divulged to Gerson Zweifach, Jessamyn Berniker and John  
19 Williams of the law firm of Williams & Connolly LLP, outside counsel to  
20 Genentech, and to their paralegals and other support staff at Williams & Connolly  
21 LLP, for the purposes of counseling Genentech and, if necessary, commencing a  
22 private AAA arbitration proceeding against UCB Celltech and/or its subsidiaries  
23 (the "Genentech/Celltech Arbitration"). The Potential Arbitration Material may  
24 be disclosed in the ordinary course of the Genentech/Celltech arbitration only to  
25 the parties, the AAA, the arbitrators and to such other witnesses or persons agreed  
26 to by the parties to the arbitration or ordered by the arbitral tribunal. Within thirty  
27 (30) days of the conclusion of the Genentech/Celltech Arbitration, including any  
28

1 appeal therefrom, Genentech shall inform Centocor of the conclusion of the  
2 arbitration and Centocor shall have the option to request the procedure  
3 enumerated in ¶ 21 of this Stipulated Protective Order, with Genentech able to  
4 take advantage of the exceptions contained therein.”  
5

6 IT IS SO ORDERED  
7

8 Dated: \_\_\_\_\_  
9

\_\_\_\_\_  
10 Hon. Mariana R. Pfaelzer  
United States District Judge  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28